Billionaire entrepreneur and frequent Trump critic Mark Cuban offered rare praise for a Trump administration initiative this week, stating the government's TrumpRx prescription drug platform is delivering significant savings to Americans on specific medications.
"Everyone expects me to criticize TrumpRx," Cuban wrote on the social media platform X. "The reality is, it's saving patients money on IVF and several other drugs. A substantial amount. In my opinion, anything that reduces costs for patients is a positive development."
Cuban's endorsement is notable given his political alignment. He has been a vocal critic of former President Donald Trump and endorsed Vice President Kamala Harris in the current presidential race. He is also the co-founder of Cost Plus Drugs, a company launched in 2022 with the mission of bypassing pharmaceutical intermediaries to lower prescription drug prices, making him a direct competitor to traditional pharmacy models.
In his post, Cuban specifically highlighted officials within the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS), crediting them for their focus on patient outcomes. "When you engage with them and see their effort, it's clear they are dedicated to doing what's right for patients," Cuban stated. He also pointed to their resistance to insurance industry demands, noting, "Don't forget they denied the price increase the insurance sector sought, which negatively impacted those stock prices."
The TrumpRx platform, launched last month, currently offers discounted prices on 54 branded prescription drugs for conditions including diabetes, cardiac arrhythmia, acid reflux, and fertility. The discounts stem from "most favored nation" pricing agreements negotiated directly between the administration and drug manufacturers.
Policy experts note the savings impact varies. Juliette Cubanski, deputy director of the Medicare policy program at KFF, explained that for insured individuals, out-of-pocket costs may often be lower than the advertised TrumpRx price. However, she confirmed that for medications not widely covered by insurance—such as certain weight-loss drugs and fertility treatments like IVF—the government platform provides a cheaper alternative. This analysis underscores the platform's role in a complex drug pricing landscape where broader healthcare funding debates continue in Congress.
Cuban's comments arrive amid a series of administration actions on domestic and foreign policy. While focusing on healthcare, the White House is simultaneously navigating other significant issues, including potential de-escalation with Iran following recent tensions in the Strait of Hormuz. Cuban concluded his assessment by suggesting both his venture and the government program are "just getting started" in their efforts to reshape drug pricing.
The acknowledgment from a high-profile Democratic supporter and industry disruptor like Cuban provides an unexpected validation of one of the administration's key healthcare policies, even as other initiatives face scrutiny. For instance, lawmakers like Rep. Adam Schiff have publicly questioned the administration's claims regarding diplomatic progress with Iran, highlighting the politically charged environment in which policy achievements are evaluated.
